CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Radient Pharmaceuticals Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Radient Pharmaceuticals Corp
2492 Walnut Avenue
Suite 100
Phone: (714) 505-4460p:714 505-4460 Tustin, CA  92780  United States Fax: (714) 505-4464f:714 505-4464

On 7/8/2014, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Radient Pharmaceuticals Corp. for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.

Business Summary
Radient Pharmaceuticals Corporation focuses on the discovery, development and commercialization of diagnostic tests that help physicians answer clinical questions related to early disease-state detection, treatment strategy, and the monitoring of disease progression or recurrence. The Company is engaged in the development, manufacturing and delivery of products focused in one area, In Vitro Diagnostic Tests for the screening, monitoring and detection of more than 14 different types of cancer. The Company has two subsidiaries: AMDL Diagnostics Inc. and Jade Pharmaceuticals Inc. The Company’s Onko-Sure in vitro diagnostic test enables physicians and their patients to monitor and/or detect solid tumor cancers. The Company’s combination immunogene therapy (CIT) seeks to build the body’s immune system and destroy cancer cells. In December 2010, the Company in partnership with Jaiva Technologies, announced the formation of NuVax Therapeutics, Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
12/31/201112/31/2011YesYes---

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board JimGreen 4/30/2014 4/30/2014
President, Director Douglas C.MacLellan 57 4/30/2014 9/1/1992
Chief Executive Officer, Director DennisCharter 4/30/2014 4/30/2014
3 additional Officers and Directors records available in full report.

Business Names
Business Name
AMDL, Inc.
Jade Pharmaceuticals Inc.
NuVax Therapeutics, Inc
Radient Pharmaceuticals Corp.
Radient Pharmaceuticals Corp.

General Information
Number of Employees: 11 (As of 12/31/2011)
Outstanding Shares: 1,347,936,151 (As of 6/15/2012)
Shareholders: 1,172
Stock Exchange: OTC
Federal Tax Id: 330413161
Fax Number: (714) 505-4464


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023